Alentis Therapeutics
We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis
69 employees · est. 2019 · Allschwil, Switzerland
ImmunoGen
Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, aesthetics, and other areas of unmet need
34 employees · est. 1981
ImmunoGen is the older company (2019 vs 1981); Alentis Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Alentis Therapeutics | ImmunoGen |
|---|---|---|
| Founded | ||
| Founded | 2019 | 1981 older |
| Headquarters | ||
| Headquarters | Allschwil, Switzerland | Not tracked yet |
| Employees | ||
| Employees | 69 larger | 34 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Series D | Acquired |
| Total Funding | ||
| Total Funding | $364.50M | $681.30M |
| Funding Rounds | ||
| Funding Rounds | 4 | 11 |
| Services | ||
| Services | Development of anti-Claudin-1 ADCs, Clinical trials for monoclonal antibodies, Fibrosis study results publication, Leadership in therapeutic development | Drug Development, Clinical Trials Management, Cancer Research and Treatment Solutions, Healthcare Professional Support |
| Target Customers | ||
| Target Customers | Cancer patients, Patients with organ fibrosis, Healthcare professionals, Biotech investors | Cancer Patients, Oncologists, Healthcare Providers, Research Institutions |
| Taxonomy | ||
| Taxonomy | Claudin-1, Tumor Treatment, Organ Fibrosis, Antibody-drug Conjugates, Oncology, Liver Fibrosis, Kidney Fibrosis, Lung Fibrosis, Cancer Therapy, Clinical-stage Biotechnology, Multi-organ Fibrosis, Drug Discovery, Drug Development, Rare Diseases, Nephrology | Antibody-drug Conjugates, Cancer Treatment, Oncology, Immunology, Neuroscience, Therapeutics Development, Targeted Antibody Payload (TAP) Technology, Metastatic Breast Cancer, Hematological Malignancies, Solid Tumors, Collaboration Agreements, Licensing Partnerships |
| Website | ||
| Website | alentis.ch | immunogen.com |
About Alentis Therapeutics
Alentis Therapeutics, founded in 2019, is a pioneering clinical-stage biotechnology company with a focus on developing breakthrough treatments for Claudin1-positive tumors and organ fibrosis. The company is based in the pharma-biotech hub of Basel, Switzerland. The company specializes in first-in-c...
About ImmunoGen
ImmunoGen, Inc. is a biotechnology innovator, harnessing the potential of antibody-drug conjugates (ADCs) to revolutionize cancer treatment. With a focus on oncology, the company combines the precision of antibodies with the effectiveness of cytotoxic drugs, aiming to target cancer cells while spari...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Alentis Therapeutics and ImmunoGen — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Alentis Therapeutics and ImmunoGen — by email.
Frequently Asked Questions
Compare Alentis Therapeutics with someone else
Start typing a company name or domain.